NCT06648317 Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
| NCT ID | NCT06648317 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Cancer Hospital & Institute |
| Condition | Lung Cancer, Non-Small Cell |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-11-21 |
| Primary Completion | 2025-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2024-11-21 with a primary completion date of 2025-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with lung lesions.
Eligibility Criteria
Inclusion Criteria: 1. 18-75 years old, male or female; 2. Heart function is normal; 3. Normal heart function; 4. Estimated survival ≥12 weeks; 5. Good follow-up compliance; 6. presence of at least one measurable target lesion according to RECIST1.1 criteria; 7. Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting the test; Fertile men and women must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the test; 8. Patients recommended by clinicians to undergo PET/CT examination for tumor diagnostic staging; 9. The subject patients could fully understand and voluntarily participate in the experiment, and signed the informed consent. Exclusion Criteria: 1. Serious abnormality of liver, kidney and blood; 2. Pregnant patients; 3. Pregnant and lactation women; 3\) unable to lie flat for half an hour; 4) Refuse to join the clinical investigator; 5) Suffering from claustrophobia or other mental diseases; 6) Other conditions that researchers deem unsuitable for participating in the experiment.
Contact & Investigator
Nan Li, MD
PRINCIPAL INVESTIGATOR
Peking University Cnacer Hospital & Institute
Frequently Asked Questions
Who can join the NCT06648317 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Lung Cancer, Non-Small Cell. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06648317 currently recruiting?
Yes, NCT06648317 is actively recruiting participants. Contact the research team at rainbow6283@sina.com for enrollment information.
Where is the NCT06648317 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06648317 clinical trial?
NCT06648317 is sponsored by Peking University Cancer Hospital & Institute. The principal investigator is Nan Li, MD at Peking University Cnacer Hospital & Institute. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.